Latest Revenue Guidance News

EROAD pivots strategically to prioritise ANZ electronic road user charging opportunities, revises FY26 guidance downward, and appoints John Scott as Executive Chair to steer growth.

Aroa Biosurgery delivered a robust September quarter with strong cash flow and record sales of its Myriad product, while reaffirming its FY26 revenue and EBITDA guidance. The company also highlighted a promising US Medicare reimbursement proposal for its Symphony product.

Telix Pharmaceuticals reports a robust 53% revenue jump in Q3 2025 and raises its full-year guidance, underpinned by key reimbursement wins and expanding clinical programs.

NRW Holdings has completed its acquisition of Fredon Industries, integrating 2,500 new employees and enhancing its electrical and mechanical services portfolio. The company has updated its FY26 guidance, projecting revenue above $4 billion and underlying EBITA between $255 million and $265 million.

Bravura Solutions has raised its FY26 revenue and cash EBITDA guidance, citing a strong British pound and increased project activity in EMEA as key growth drivers.

Telix Pharmaceuticals has secured FDA agreement on a resubmission plan for its glioma imaging agent TLX101-CDx, aiming for a Q4 2025 filing that includes additional efficacy data. The FDA signals likely expedited review, underscoring the unmet medical need.

Amaero Ltd has updated its FY2026 financial guidance, forecasting revenue between A$30 million and A$35 million; a staggering 800%-900% increase year-over-year; and announced a A$50 million capital raise to expand production capacity and reduce costs.

Biome Australia Limited projects its Q1 FY26 sales revenue to exceed $5.5 million, breaking its previous quarterly record and signaling continued momentum in the microbiome health sector.

Bioxyne Limited projects FY2026 revenue between $65 million and $75 million, driven by expansion in Australian medical cannabis and a landmark $5.8 million contract in Germany.

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.

Fluence Corporation Limited reported a robust 64.7% revenue increase to $33.1 million in H1 2025, driven by the Ivory Coast Addendum project and a strategic pivot to high-margin solutions. The company improved EBITDA to a positive $0.1 million and reduced fixed costs, signaling progress in its operational realignment.

FINEOS Corporation delivered solid first-half results with revenue growth and improved profitability, while navigating currency challenges that temper full-year guidance.